IGM Biosciences Surpasses Earnings and Revenue Estimates in Q2, Shares Down 79.4% YTD
ByAinvest
Thursday, Jul 31, 2025 9:11 pm ET1min read
IGMS--
IGM Biosciences reported Q2 earnings of $1.58 per share, beating the Zacks Consensus Estimate by 626.67%. Revenues were $143.62 million, surpassing the Zacks Consensus Estimate by 4,388.22%. The company has topped consensus revenue estimates two times over the last four quarters. Shares have lost 79.4% since the beginning of the year. The Zacks Rank is #5 (Strong Sell) due to an unfavorable estimate revisions trend.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet